Clinical trials: Coronary Bifurcation Stenosis
Percutaneous Coronary Intervention
The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions
To evaluate the safety and effectiveness of paclitaxel-eluting coronary artery balloon dilation catheter (DIOR) in revascularization of coronary bifurcation lesions compared with paclitaxel-eluting balloon (Bingo), and to provide…
- Trial name
- BEYOND-II (NCT03820622)
- Testing
- Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo)
- Where
- 13 sites in China
- Volunteers
- 220 people
- Sponsor
- CCRF Inc., Beijing, China
Angina Pectoris, Angina, Unstable
Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study
This pilot study is going to examine the hypothesis that in coronary arteries, soft lesions that contain lipid cores, but are not calcified or fibrotic and are located in proximity to side branches, are associated with side…
- Conditions
- Angina Pectoris, Angina, Unstable, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00905671
- Testing
- LipiScan Coronary Imaging Catheter
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Infraredx
Coronary Disease
Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent
The purpose of this trial is to assess the safety and efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the treatment of single de novo bifurcation lesions in native coronary arteries with a main branch…
- Trial name
- BIPAX (NCT01308229)
- Testing
- Nile PAX® paclitaxel-eluting coronary stent
- Where
- 10 sites in Brazil, Bulgaria and 5 more
- Volunteers
- 102 people
- Sponsor
- MINVASYS
Coronary Stenosis, Drug-coated Balloon
Bingo Drug-Coated Balloon in Real World
The purpose is to observe and evaluate the safety and efficacy of Bingo drug-coated balloon in the real world.
- Conditions
- Coronary Stenosis, Drug-coated Balloon, De Novo Stenosis, Coronary Artery Disease in Transplanted Heart Accelerated
- Trial name
- NCT04234893
- Where
- China
- Volunteers
- 805 people
- Sponsor
- Yinyi(Liaoning) Biotech Co., Ltd.
Coronary Disease
Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)
The purpose of this study is to assess the safety and efficacy of the Danubio Paclitaxel Eluting Balloon for the treatment of side branches of de novo bifurcation lesions in native coronary arteries.
- Trial name
- DEBSIDE (NCT01485081)
- Testing
- Danubio paclitaxel-eluting balloon
- Where
- 7 sites in France
- Volunteers
- 52 people
- Sponsor
- MINVASYS
Coronary Stenosis
POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
The primary objective of this study is to study the safety and efficacy of the BiOSS LIM C with respect to Patient oriented Composite Endpoint (PoCE) at 12 months in a "real world" left-main bifurcation population and as compared…
- Trial name
- POLBOS-LM (NCT03508219)
- Testing
- BiOSS LIM C
- Where
- 15 sites in France, Italy and 1 more
- Volunteers
- 130 people
- Sponsor
- ECRI bv
Coronary Artery Disease
Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions
This study in bifurcated coronary lesions compares the new technology of the paclitaxel-eluting balloon with the usual technique until now of "provisional stenting" with the paclitaxel-eluting stent in the main branch.
- Trial name
- BABILON (NCT01278186)
- Testing
- Balloon angioplasty, Stent implantation
- Where
- 9 sites in Spain
- Volunteers
- 190 people
- Sponsor
- B.Braun Surgical SA
Bifurcation Lesions, Drug Eluting Balloon
Bingo Drug-eluting Balloon in Bifurcation
The purpose is to observe and evaluate the safety and efficacy of Bingo drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.
- Trial name
- NCT02325817
- Testing
- Drug-eluting balloon, Uncoated ballloon
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Yinyi(Liaoning) Biotech Co., Ltd.